MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia withthe t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia

Citation
K. Sugita et al., MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia withthe t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia, GENE CHROM, 27(3), 2000, pp. 264-269
Citations number
27
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
GENES CHROMOSOMES & CANCER
ISSN journal
1045-2257 → ACNP
Volume
27
Issue
3
Year of publication
2000
Pages
264 - 269
Database
ISI
SICI code
1045-2257(200003)27:3<264:MFTIAT>2.0.ZU;2-D
Abstract
We describe a boy with Fanconi anemia (FA) who developed acute lymphoblasti c leukemia (ALL) (FAB-L I) followed by acute myeloid leukemia (AML) (FAB-M5 ) at relapse. The patient was diagnosed with early pre-B-cell ALL without p receding aplastic anemia and was treated with ALL-oriented chemotherapy whi ch included doxorubicin (a total dose of 140 mg/m(2) administered), which i s a topoisomerase II inhibitor. Complete remission was obtained, but after 38 weeks AML developed. The karyotype of ALL cells at diagnosis showed 46,X Y, and that of AML cells at relapse was 46,XY, t(11;16)(q23;p13). An MLL ge ne rearrangement and MLL-CBP chimeric mRNA were found in AML, but not in AL L. A diagnosis of FA was confirmed by an increased number of chromosomal br eaks and rearrangements in peripheral blood lymphocytes cultured with mitog en in the presence of mitomycin C. We conclude that this FA patient develop ed ALL followed by a therapy-related t(11;16)-AML resulting in an MLL-CBP f usion. Further examination of such patients would shed light on leukemogene sis in FA patients. (C) 2000 Wiley-Liss, Inc.